Pregled bibliografske jedinice broj: 1117658
Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer
Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer // Cancer epidemiology biomarkers & prevention, 22 (2013), 7; 1313-1318 doi:10.1158/1055-9965.epi-13-0053 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1117658 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer
Autori
De Sanjose, Silvia ; Wheeler, Cosette M. ; Quint, Wim G.V. ; Hunt, William C. ; Joste, Nancy E. ; Alemany, Laia ; Xavier Bosch, F. ; Myers, Evan R. ; Castle, Philip E.
Kolaboracija
RIS HPV TT Study Group
Izvornik
Cancer epidemiology biomarkers & prevention (1055-9965) 22
(2013), 7;
1313-1318
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
HPV
Sažetak
The age-specific occurrence of cervical cancer related to human papillomavirus (HPV) genotypes HPV16 and HPV18, the two targeted by current HPV vaccines, is not well described. We therefore used data from two large, tissue-based HPV genotyping studies of cervical cancer, one conducted in New Mexico (n = 744) and an International study restricted to cancers (n = 1, 729) from Europe, North America, and Australia to represent those regions with widely available cervical cancer screening facilities. HPV results were categorized as HPV16- or HPV18-positive (HPV16/18) versus other HPV genotype. We observed a decreasing proportion of HPV16/18-positive cancers with increasing age in the International study (Ptrend < 0.001) and New Mexico study (Ptrend < 0.001). There was no heterogeneity in the relationship between age of diagnosis and the proportion of HPV16/18-positive cancers between studies (P = 0.8). Combining results from the two studies (n = 2, 473), the percentages of HPV16/18-positive cases were 77.0% [95% confidence interval (CI): 75.1%–78.9%] for women less than 65 years old and 62.7% [95% confidence interval (CI): 58.4%–66.9%] for women aged 65 and older (P < 0.001). In women who are under the age of 25 and have been vaccinated before becoming sexually active, the cervical cancer incidence is expected to be approximately 3.5 per million by 2020. HPV vaccination against HPV16/18 may have a greater impact on cervical cancers in women under 65 than in women aged 65 and older. These data will inform the age-specific impact of HPV vaccination and its integration with cervical cancer screening activities
Izvorni jezik
Engleski
Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
Napomena
Ova studija je nastala kao rezultat rada kolaboracije "Retrospective International Survey and HPV Time Trends Study Group" u kojoj su sudjelovali sljedeći hrvatski znanstvenici: Magdalena Grce, Ivan Sabol, Sonja Džebro i Mara Dominis.
Vidi: Acknowledgments
POVEZANOST RADA
Ustanove:
Klinička bolnica "Merkur",
Institut "Ruđer Bošković", Zagreb
Profili:
Magdalena Grce
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE